crizotinib (Xalkori)
Jump to navigation
Jump to search
Indications
- non small cell lung carcinoma with mutations in the anaplastic lymphoma kinase (ALK) protein; not recommended (NICE)
Dosage
Adverse effects
- nausea (55%) & vomiting (39%) most common
- hepatotoxicity (< 1%), may be fatal[2]
Mechanism of action
- selective, ATP-competitive, small molecule, orally bioavailable inhibitor of anaplastic lymphoma kinase (ALK) & MET/HGF receptor tyrosine kinases[1]
More general terms
Additional terms
References
- ↑ 1.0 1.1 Bang Y et al, Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). J Clin Oncol 28:18s, 2010 (suppl; abstr 3) http://abstract.asco.org/AbstView_74_50854.html
- ↑ 2.0 2.1 Drug-induced hepatotoxicity with fatal outcome has occurred with Xalkori (crizotinib) Pfizer Bulletin: Dec 29, 2013